Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from HUTCHMED (China) ( (HK:0013) ) is now available.
HUTCHMED announced significant results from the FRUSICA-2 registration trial, showcasing the efficacy of the fruquintinib and sintilimab combination in treating advanced renal cell carcinoma. The trial demonstrated notable improvements in progression-free survival and objective response rates compared to existing monotherapies, indicating the potential of this combination to enhance second-line treatment strategies for this challenging disease. The results have led to a New Drug Application being accepted for review by the China National Medical Products Administration, potentially impacting treatment options for renal cell carcinoma patients.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
YTD Price Performance: 9.71%
Average Trading Volume: 10,640,152
Technical Sentiment Signal: Hold
Current Market Cap: HK$21.58B
See more data about 0013 stock on TipRanks’ Stock Analysis page.